Study NCT06427876 is a Japan post-marketing observational study in pediatric intractable asthma evaluating real-world safety and effectiveness of Fasenra (benralizumab) SC 30 mg/10 mg. Drug/type/mechanism: Benralizumab is a humanized, afucosylated IgG1 monoclonal antibody (biologic immunotherapy) that binds IL-5 receptor alpha (IL-5Rα) on eosinophils and basophils, blocking IL-5 signaling and engaging FcγRIIIa on NK cells to drive ADCC-mediated depletion of these cells. Targets/pathways: Eosinophils (primary) and basophils, IL-5/IL-5R signaling within type 2 (Th2) inflammatory pathways central to eosinophilic asthma.